Funding Opportunities
|
RE: Announcing a Request for Proposals (RFP) for COVID-19 Investigator Sponsored Research (ISR)
|
| Dear Investigators,
At Bristol Myers Squibb, we understand that this is a difficult and busy time for all of our investigators as you work on the front lines dealing with the COVID-19 outbreak. First and foremost, we want to let you know that BMS is focused on protecting our workforce’s health and safety, ensuring a continued supply of our medicines to patients and supporting relief efforts across the globe. BMS will take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to patients who depend on us.
BMS is also committed to joining the broader academic and scientific community in the fight against COVID-19. We continue to closely monitor the evolving situation across the globe, to this end, we would like to provide a few updates on how we are evolving our Investigator Sponsored Research (ISR) program related to COVID-19.
To ensure we are supporting the best scientific inquiries addressing the unmet needs of patients, BMS has decided to modify its COVID-19 ISR application process, changing from a rolling submission process to a time-period specific “Request for Proposal (RFP) process”. The RFP process will be published on BMS.com along with COVID-19 specific “Areas of Interest” on July 20th, 2020. This will enable BMS to open a submission period from the end of July through August 15th, 2020 to begin accepting COVID-19 concept submissions. Our expectation is that we will receive a large number of proposals, leading to a very competitive process through which we will approve between 5-10 of the best scientific concepts, each with a budget of up to $2M. · The new process will be limited to COVID-19 concepts only. · Due to the alliance between Pfizer and BMS, COVID-19 concepts involving apixaban will continue with its existing review processes outside of this RFP. · All non COVID-19 proposals will continue their existing processes.
For further information, please contact your BMS Medical Representative or go to BMS.com for additional details.
As we share these timelines, I believe we can all appreciate that the ongoing pandemic has necessitated flexibility in the way we work. Thus, given the unpredictability of the ongoing COVID-19 pandemic, these timelines are subject to change. As always, your local medical/field medical point will be the source of information should there be any questions or queries about changes to the ISR process. Thank you in advance for your understanding and continued support during this period of transition.
Sincerely,
Paul Haluska MD, PhD Vice President, Global Medical, Medical Data Generation Bristol-Myers Squibb Company
|
Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01 – Clinical Trial Optional)
NIMHD is partnering with National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA) and National Cancer Institute (NCI) to support a new funding opportunity announcement (FOA): PA-20-172. The FOA is titled: Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01 – Clinical Trial Optional).
The purpose of this FOA is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations across communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinas, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.
Application First Due Date: October 5, 2020.
For inquiries related to NIMHD’s scientific and research involvement concerning this FOA, contact Dr. Larissa Avilés-Santa at avilessantal@nih.gov. View the full funding opportunity announcement for more information.
For more information: https://grants.nih.gov/grants/guide/pa-files/PA-20-172.html?utm_medium=email&utm_source=govdelivery
NIH R01 Funding for COVID-19 Research
https://grants.nih.gov/grants/guide/pa-files/PAR-20-237.html
This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.
This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
Through its Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative, NIH aims to understand the factors that lead to COVID-19–related health disparities so that effective interventions can be implemented. As part of this initiative, NIMHD is supporting 2-year community-engaged Testing Research Projects. These projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of testing among underserved populations.
This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html
This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.
Additionally, the OSU Office of Research is collecting NIH and other agencies guidance here: https://research.osu.edu/news-events/coronavirus-and-your-research-program/
Publications
Cultivating emergency physician behavioral empathy to improve emergency department care for pain and prescription opioid misuse by Maher Kazimi MBBS, MPH, Thomas Terndrup, MD, Raymond Tait, PhD, Jennifer A. Frey PhD, CCRP, Scott Strassels PharmD, PhD, Geremiah Emerson MD, Knox H. Todd MD, MPH.
Are you contemplating working with a unpaid summer/volunteer student?
SHARP can help you work out the logistics. We can arrange for virtual access for OSU affiliates at no cost, and virtual access for non-OSU affiliates for a fee (to set up a virtual machine for them to remote to).
For more information, contact Judy M. Opalek, PhD (judy.opalek@osumc.edu)
SHARP Summer Break
Our SHARP weekly meetings are taking a summer break from June 24th to August 5th. We will see you again on August 12th!
SHARP Staff – Return to Campus
We are in the midst of our Return to Campus plan and you may be seeing us in the office more often. We need to adhere to the social distancing requirements in our shared space, and we will be working on modified schedules until a full return is feasible. All SHARP staff continue to be reachable by phone, email, and text, whether in the office or working remotely. We appreciate your patience during this time.
Please note that the SHARP staff are working 100% remotely at this time and are still fully available for virtual meetings and discussion. We have nearly every normal tool at our disposal during this time and are only limited by face-to-face interactions and campus-based physical resources. If you have any questions or concerns—reach out!
